BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34015818)

  • 21. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.
    Kleinschmidt-DeMasters BK; Mulcahy Levy JM
    Clin Neuropathol; 2018; 37 (2018)(2):53-63. PubMed ID: 29393845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
    Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
    Front Oncol; 2020; 10():795. PubMed ID: 32582540
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinicoradiological characteristics of primary spinal cord H3 K27M-mutant diffuse midline glioma.
    Cheng L; Wang L; Yao Q; Ma L; Duan W; Guan J; Zhang C; Wang K; Liu Z; Wang X; Wang Z; Wu H; Chen Z; Jian F
    J Neurosurg Spine; 2022 Feb; 36(2):303-314. PubMed ID: 34560639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging.
    Jung JS; Choi YS; Ahn SS; Yi S; Kim SH; Lee SK
    Neuroradiology; 2019 Mar; 61(3):313-322. PubMed ID: 30662997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.
    Aboian MS; Solomon DA; Felton E; Mabray MC; Villanueva-Meyer JE; Mueller S; Cha S
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):795-800. PubMed ID: 28183840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults.
    Schulte JD; Buerki RA; Lapointe S; Molinaro AM; Zhang Y; Villanueva-Meyer JE; Perry A; Phillips JJ; Tihan T; Bollen AW; Pekmezci M; Butowski N; Oberheim Bush NA; Taylor JW; Chang SM; Theodosopoulos P; Aghi MK; Hervey-Jumper SL; Berger MS; Solomon DA; Clarke JL
    Neurooncol Adv; 2020; 2(1):vdaa142. PubMed ID: 33354667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
    Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
    J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. H3 G34-mutant high-grade glioma.
    Lim KY; Won JK; Park CK; Kim SK; Choi SH; Kim T; Yun H; Park SH
    Brain Tumor Pathol; 2021 Jan; 38(1):4-13. PubMed ID: 32995948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diffuse midline glioma].
    Saito R
    No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
    Low JT; Wang SH; B Peters K
    CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report.
    Babarczy K; Reisz Z; Szabo E; Rajda C; Vecsei L; Bodi I; Klivenyi P; Hortobagyi T; Szalardy L
    Folia Neuropathol; 2020; 58(4):377-385. PubMed ID: 33480242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
    Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
    Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of magnetic resonance imaging characteristics in discriminating H3 K27M-mutant gliomas from wildtype gliomas in spinal cord.
    Zhao B; Yao J; Wang J; Li J; Shi W; Zhang C; Zhao X; Qiao J; Ma Y; Xu Y; Zheng Z
    Neurol Sci; 2024 Jun; 45(6):2845-2851. PubMed ID: 38228940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements.
    Chen H; Hu W; He H; Yang Y; Wen G; Lv X
    Eur J Radiol; 2019 May; 114():152-159. PubMed ID: 31005167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
    J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
    Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
    World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk stratification of H3 K27M-mutant diffuse midline gliomas based on anatomical locations: an integrated systematic review of individual participant data.
    Vuong HG; Le HT; Jea A; McNall-Knapp R; Dunn IF
    J Neurosurg Pediatr; 2022 Jul; 30(1):99-106. PubMed ID: 35535848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.